Nasdaq btai.

Follow. NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 …NEW HAVEN, Conn., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.25 May 2023 ... Healthcare Stocks on the Move Thursday: ELEV, CDIO, HSCS, XBIT, ANNX, BIOC, BTAI, BHG · These Healthcare stocks are trading higher: · These ...

This forecast implies upside of 128%. Thus, BTAI could be one of the best short-squeeze stocks. Aravive (ARAV) Source: Epic Cure / Shutterstock. Hailing from Houston, Texas, Aravive (NASDAQ:ARAV) ...

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated BioXcel Therapeutics Stock (NASDAQ:BTAI), Short Interest Report. Short interest for BioXcel Therapeutics gives investors a sense of the degree to which investors are betting on the decline of ...

Nov 15, 2023 · Good news is that we have both equity as well as potential debt option in addition to, as I mentioned previously, partnering, which can be outside the U.S. for Alzheimer’s-related agitation ... BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...BioXcel Therapeutics ( NASDAQ:BTAI ) Third Quarter 2023 Results Key Financial Results Net loss: US$50.5m (loss widened... Simply Wall St.•17 days ago.Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.About Insider Activity. Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company ...

Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for BTAI stock stock is $12.2, which predicts an increase of 213.62%. The lowest target is $4.00 and the highest is $22. …

Jul 5, 2023 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioXcel Therapeutics Inc (Symbol: BTAI), where a total of 14,591 contracts have traded ...

NEW HAVEN, Conn., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics, Inc. (BTAI.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioXcel Therapeutics, ...

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Positive Topline Results for TRANQUILITY II; Possible Trial Conduct Issues at One Clinical Site On June 29, 2023 ...NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...When is BioXcel Therapeutics's earnings date? BioXcel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on BTAI's earnings history.Fintel reports that on June 30, 2023, Mizuho reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation.. Analyst Price Forecast Suggests 205.94% Upside. As of June 2 ...(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 118.87% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.69%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.54%.

NEW HAVEN, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics to host conference call today at 8:00 a.m. ET. NEW HAVEN, Conn., June 29, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company ...

NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Nov 30, 2023 · The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91. Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023. NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST 3.9999 +0.10 …Dec 3, 2023 · 2017. 183. Vimal Mehta. https://www.bioxceltherapeutics.com. BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or ... BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...On November 14, 2023, BioXcel Therapeutics Inc ( NASDAQ:BTAI) released its 8-K filing, announcing strategic advancements and financial results for the third quarter ended September 30, 2023. The ...BioXcel Therapeutics, Inc. Common Stock (BTAI) Nasdaq Listed. DATA AS OF Nov 12, 2021. 0.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...

Shares of BioXcel Therapeutics ( BTAI -1.80%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...

Dec 1, 2023 · When is BioXcel Therapeutics's earnings date? BioXcel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on BTAI's earnings history. Nov 17, 2023 · On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days. NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) recently conducted a meeting with the FDA regarding the development pathway for BXCL501 for the treatment of agitation associated with Alzheimer’s disease (AD). Following receipt of the meeting minutes, the company announced that it was aligned with the FDA’s recommendation to conduct an …NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced proof-of-concept data from its Phase 1b study of ...BioXcel Therapeutics Inc. Follow. Share. $3.93. After Hours: $3.90. (0.76%) -0.030. Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer. search Compare to. BTAI DEADLINE: ROSEN, ... (NASDAQ: BTAI) between... BTAI: 3.93 (+2.61%) BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options PR Newswire - Sat Sep 2, 6:00AM CDT ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr.BioXcel Therapeutics Inc. Follow. Share. $3.93. After Hours: $3.90. (0.76%) -0.030. Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer. search Compare to. This forecast implies upside of 128%. Thus, BTAI could be one of the best short-squeeze stocks. Aravive (ARAV) Source: Epic Cure / Shutterstock. Hailing from Houston, Texas, Aravive (NASDAQ:ARAV) ...Instagram:https://instagram. the best forex strategy1979 dollar coinsbest stock for electric carswest pharmaceutical services inc. BioXcel Therapeutics, Inc. BTAI is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. usaa motorcycle insurance ratesasml stock forecast More specifically, Citadel Investment Group was the largest shareholder of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), with a stake worth $32.5 million reported as of the end of September. masterworks stock price Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. BioXcel Therapeutics, Inc. Common Stock (BTAI) Pre-Market Stock Quotes - Nasdaq ... Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing.